Characterization of a fusion protein under native and denaturing conditions with maXis II

Protein Clipping Variant Analysis of Vedolizumab using dedicated workflows in BioPharma Compass Proteolytic degradation of biopharmaceuticals during their life cycle can pose health risks and require dedicated analysis. Abstract In this work we used enzymatically introduced antibody truncation variants as…

Routine analysis of drug to antibody ratio and drug distribution with maXis II Antibody drug conjugates (ADC) are small molecule conjugated mAbs. These are rapidly emerging complex biological molecules in the biopharma space. Abstract Characterization of ADC’s includes intact mass…

Next-generation MALDI top-down sequencing of protein biotherapeutics – expanding the scope of timsTOF technology Next-generation MALDI top-down sequencing (MALDI-TDS) improves top-down sequence analysis of biopharmaceutical proteins, as demonstrated in this note for adalimumab subunits, recombinant SARS-CoV-2 S-glycoprotein RBD expression products,…

Fully automated glycoform profiling and sequence validation of the NIST reference antibody Abstract Two key elements assessed during the analysis of mAb biotherapeutics are the glycosylation profile and the primary sequence. Using the NIST antibody as a model, three complementary…